Loading...
 
Mediterr J Rheumatol 2017;28(1):1-3
Advances in Systemic Lupus Erythematosus (SLE): A case for optimism
Authors Information

Joint Rheumatology Program, Medical School, National and Kapodestrian University of Athens and 4th Department of Medicine, Attikon University Hospital, Athens, Greece

References
  1. Bertsias G K, Salmon J E, Boumpas D T. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010;69:1603-11.
  2. Tsokos G C. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21.
  3. Bertsias G K, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol 2013;9:687-94.
  4. Durga D P, Negi V S. Interferon targeted therapies in systemic lupus erythematosus. Mediterr J Rheumatol 2017;28(1):13-9.
  5. Galanopoulos N, Christoforidou A, Bezirgiannidou Zoe, Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterr J Rheumatol 2017;28(1):20-6.
  6. Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol 2017;28(1):4-12.
  7. Kontaki E, Boumpas D T. Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J Autoimmun 2010;35:206-11.
  8. Crow M K, Olferiev M, Kirou K A. Targeting of type I interferon in systemic autoimmune diseases. Transl Res 2015;165:296-305.
  9. Liu Y, Chen S, Sun Y, et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. Medicine (Baltimore) 2016;95:e5565.
  10. Ugarte-Gil M F, Acevedo-Vasquez E, Alarcon G S, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis 2015;74:1019-23.
  11. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013;27(3):329-40.
  12. Frangou E A, Bertsias G K, Boumpas D T. Gene expression and regulation in systemic lupus erythematosus. Eur J Clin Invest 2013;43:1084-96.
  13. Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell 2016;165:1548-50.
  14. Franklyn K, Lau C S, Navarra S V, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75:1615-21.
  15. Liu Z, Zhang H, Xing C, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26.